# EDGAR Filing Document

**Accession Number:** 0001958086
**File Stem:** 0001193125-26-037789
**Filing Date:** 2026-2
**Character Count:** 52273
**Document Hash:** 0bb8cba1c167557eb8160fce4a1c2fb3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-037789.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0001193125-26-037789

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260204

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260204

**DATE AS OF CHANGE**: 20260204

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Core Laboratories Inc. /DE/
- **CENTRAL INDEX KEY:** 0001958086
- **STANDARD INDUSTRIAL CLASSIFICATION:** OIL, GAS FIELD SERVICES, NBC [1389]
- **ORGANIZATION NAME:** 01 Energy & Transportation
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41695
- **FILM NUMBER:** 26599176

**BUSINESS ADDRESS:**
- **STREET 1:** 6316 WINDFERN ROAD
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77040
- **BUSINESS PHONE:** 713-328-2673

**MAIL ADDRESS:**
- **STREET 1:** 6316 WINDFERN ROAD
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77040

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Core Laboratories Luxembourg S.A.
- **DATE OF NAME CHANGE:** 20221213

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** February 4, 2026

------

CORE LABORATORIES INC.

(Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-41695 | 98-1164194 |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| **6316 Windfern Road** |  |  |
| Houston**,** TX |  | 77040 |
| (Address of principal executive offices) |  | (Zip Code) |

---

Registrant's Telephone Number, Including Area Code**: (**713**)** 328-2673

**Not Applicable**

(Former name or former address, if changed since last report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock (par value $0.01)<br> CLB | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On February 4, 2026, Core Laboratories Inc. issued a press release announcing its financial results for the fourth quarter of 2025 and year ending December 31, 2025.

**Item 7.01 Regulation FD Disclosure.**

On February 4, 2026, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on February 16, 2026 and payable March 9, 2026.

The full text of the press release is set forth in Exhibit 99.1 attached hereto.

The information in this Report and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly stated by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) *Exhibits* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 [<u>Press release issued on February 4, 2026 \*</u>](clb-ex99_1.htm)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

\* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Exchange Act.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Core Laboratories Inc. | Core Laboratories Inc. |
| Dated: February 4, 2026 | By | /s/ Christopher S. Hill |
|  |  | Christopher S. Hill |
|  |  | Chief Financial Officer |

---

------

## Exhibit 99.1

**Exhibit 99.1**

![img77179564_0.gif](img77179564_0.gif)

**<u>FOR IMMEDIATE RELEASE</u>** 

**CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FOURTH QUARTER REVENUE OF $138.3 MILLION, UP 3% SEQUENTIALLY AND UP 7% YEAR-OVER-YEAR**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FOURTH QUARTER OPERATING INCOME OF $15.8 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF OVER 11%, DOWN 100 BASIS POINTS SEQUENTIALLY AND 80 BASIS POINTS YEAR-OVER-YEAR**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.21, DOWN 4% SEQUENTIALLY AND YEAR-OVER-YEAR**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FOURTH QUARTER FREE CASH FLOW OF $5.1 MILLION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **NET DEBT REDUCED BY $1.2 MILLION; LEVERAGE RATIO IMPROVED TO 1.09**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **COMPANY REPURCHASED 363,207 SHARES OF COMMON STOCK, FOR $5.7 MILLION AGGREGATE PURCHASE PRICE**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **COMPANY ANNOUNCES Q1 2026 QUARTERLY DIVIDEND** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FULL YEAR REVENUE OF $526.5 MILLION, UP SLIGHTLY** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FULL YEAR OPERATING INCOME OF $56.5 MILLION; EX-ITEMS, $58.7 MILLION, DOWN 10%** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FULL YEAR GAAP EPS OF $0.68 UP 3%; EX-ITEMS, EPS OF $0.75, DOWN 14%** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FULL YEAR FREE CASH FLOW OF $26.0 MILLION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FULL YEAR NET DEBT REDUCED BY $18.7 MILLION OR OVER 17%**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **FULL YEAR COMPANY REPURCHASED APPROXIMATELY 1.2 MILLION SHARES OF COMMON STOCK, $15.5 MILLION AGGREGATE PURCHASE PRICE**

HOUSTON (February 4, 2026) – Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported fourth quarter 2025 revenue of $138,300,000. Core's operating income was $15,800,000, with earnings per diluted share ("EPS") of $0.15, all in accordance with U.S. generally accepted accounting principles ("GAAP"). Operating income, ex-items, a non-GAAP financial measure, was $15,700,000, yielding operating margins of over 11% and EPS, ex-items, of $0.21. For the full year 2025, revenue of $526,500,000 was up slightly compared to 2024, generating operating income on a GAAP basis of $56,500,000 and operating income, ex-items, of $58,700,000. The Company's full year EPS, ex-items, was $0.75. A full reconciliation of non-GAAP financial measures is included in the attached financial tables.

Core's CEO, Larry Bruno, stated, "Core Lab's fourth quarter results were highlighted by sequential and year-over-year revenue growth that exceeded our provided guidance range for the quarter. This was driven

------

by strong international demand for the Company's proprietary technologies, which helped offset a seasonally soft U.S. land market. Core Lab's recent investments to bring unconventional reservoir rock testing capabilities to the Middle East produced immediate returns, as the Company executed and expedited a large unconventional reservoir rock analytical program for a National Oil Company ("NOC") during the fourth quarter. Also during the fourth quarter, Core returned free cash to its shareholders through the Company's quarterly dividend and by repurchasing 363,207 shares of Company stock, marking five consecutive quarters of share repurchases. For full year 2025, the Company repurchased approximately 1.2 million shares, or over 2.5% of the Company's outstanding share count. Aligned with our long-standing strategy, Core remains committed to returning excess free cash to its shareholders, while maintaining a strong balance sheet and executing our strategic growth initiatives. As the Company celebrates its 90th anniversary, Core's consistent performance reflects the strength of our asset-light business model, global technology leadership, client focus, and long-standing commitment to shareholder returns."

*<u>Reservoir Description</u>*

Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately 80% of revenue sourced from projects originating outside the United States. Revenue for Reservoir Description in the fourth quarter of 2025 was $92,300,000, up 5% sequentially and up over 6% from last year. Operating income on a GAAP basis was $12,800,000. Operating income, ex-items, was $12,700,000, up 9% sequentially, yielding operating margins of 14%, with incremental margins of 27%. Sequential incremental margins were negatively impacted by three factors: 1) expanded international sanctions arising from the Russia-Ukraine conflict, 2) pass-through revenue with low margins associated with a collaborative project, and 3) increased labor costs. For the full year 2025, the segment's revenue of $347,700,000, up slightly from last year, generated operating income on a GAAP basis of $43,900,000, and operating income, ex-items, of $42,900,000, yielding operating margins of over 12%.

In the fourth quarter, Core Lab successfully completed phase one of a comprehensive study for an NOC in the Middle East focused on evaluating unconventional reservoir rock properties. Unconventional reservoirs require highly specialized laboratory workflows to accurately determine rock properties, reservoir quality, and production potential. The analytical program leveraged Core Lab's array of internally developed laboratory technologies, including high-frequency nuclear magnetic resonance, NANOk™ Nano Permeametry, and the Company's Shale Matrix Permeameter. These complementary technologies delivered the precision, repeatability, and scalability required to meet the operator's technical objectives as they evaluate these challenging reservoirs. The next phase of the program will focus on correlating newly generated laboratory data with legacy datasets and downhole log response, yielding a more robust reservoir model and improved forecasts of long-term production potential.

Also during the fourth quarter, Core Lab experienced an increase in regional study sales focused on Africa and Brazil, reflecting renewed industry interest in exploration activity. Demand was particularly strong along the West African Offshore Equatorial Margin, including Côte d'Ivoire, Ghana, Gabon, and Liberia, as well as North Africa. In addition, interest heightened along the South Atlantic Margin in Brazil's offshore Pelotas Basin. Collectively, demand for Core Lab's data sets highlight the Company's reputation as a trusted, independent provider of geological insights that enable clients to reduce uncertainty and make informed exploration and development decisions.

------

*<u>Production Enhancement</u>*

Production Enhancement operations, which are focused on complex completions in unconventional oil and gas reservoirs in the U.S., as well as conventional and unconventional projects across the globe, posted fourth quarter 2025 revenue of $46,000,000, down slightly sequentially and up over 8% year-over-year. Operating income for the fourth quarter on both a GAAP basis and ex-items, was $3,000,000, yielding operating margins, ex-items, of 7%, expanding 300 basis points year over year. Sequential margin performance was negatively impacted by increased raw material expenses associated with tariffs and a provision for a potentially uncollectible receivable balance. There are no additional receivables at risk associated with this contract. For the full year 2025, the segment's revenue of $178,800,000 increased slightly compared to 2024, generated operating income on a GAAP basis of $12,100,000, and operating income, ex-items, of $15,100,000, up over 25% and up 165 basis points, despite lower levels of U.S. onshore well completion activity.

In the fourth quarter of 2025, Core Lab successfully completed an offshore plug and abandonment project on a deepwater Gulf of America well using its proprietary PAC™ technology. Core's PAC™ system was selected to enable annular access for permanent cement barrier placement where conventional section milling presented operational and scheduling risks. The operation was completed in approximately four days, exceeding client expectations. Based on typical offshore milling durations and current day rates, the use of Core Lab's PAC™ system is estimated to have reduced execution time by up to five days and lowered well cost by approximately half-million dollars. Core's PAC™ system is a widely proven and accepted technology, and adoption of this technology is expanding beyond its traditional geographic markets.

Also, during the fourth quarter, a major deepwater operator engaged Core Lab to deploy its innovative, thru-pipe top-of-cement tracing technology using Core's proprietary SpectraStim® tracers for their riserless completions. Riserless cementing is often employed offshore as a cost-effective technique for setting conductor and surface casings where the seabed is unstable or where shallow gas hazards exist. Due to the instability of these zones, lightweight, low-density foamed cement is often utilized for setting these shallow casing strings. It is very important to ensure zonal coverage with the foamed cement. However, because foamed cement has a low acoustic impedance, traditional cement bond logs are notoriously ineffective in evaluating coverage. Core's SpectraStim® tracing successfully confirmed zonal coverage by the foamed cement and satisfied the offshore regulatory requirements in a cost-effective manner.

*<u>Liquidity, Free Cash Flow, Share Repurchases, and Dividend</u>*

Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the fourth quarter of 2025, cash from operations was $8,100,000 and capital expenditures associated with operations were $3,000,000, yielding FCF of $5,100,000. The Company had cash from operations of $37,200,000 and generated $26,000,000 of FCF for the twelve months ending December 31, 2025.

As mentioned in the Company's prior earnings releases, in February 2024, fire damaged a building on the campus of Core Lab's Advanced Technology Center in Aberdeen, Scotland. Losses caused by the fire are covered by Core Lab's property and casualty insurance. Insurance proceeds and the capital expenditures associated with replacing the equipment and restoring the building are disclosed separately in the investing

------

section of the cash flow statement. Capital expenditures associated with these items were $700,000 for the fourth quarter of 2025 and $3,400,000 for the twelve months ending December 31, 2025. Capital expenditures associated with these items are not included in the calculation of FCF.

On October 1, 2025, Core Lab completed the acquisition of Brazilian-based Solintec Consultoria E Servicos De Geologia Ltda. ("Solintec"), for an initial cash payment of approximately $2,300,000.

In the fourth quarter of 2025, Core Lab repurchased 363,207 shares at an aggregate purchase price of approximately $5,700,000.

As of December 31, 2025, Core's net debt (defined as long-term debt less cash and cash equivalents) was $90,200,000, which was reduced by $1,200,000 during the quarter. Also, during the fourth quarter of 2025, the Company's leverage ratio (calculated as total net debt divided by trailing twelve months adjusted EBITDA) improved to 1.09, and is now at its lowest level in nine years. For the full year, Core's net debt was reduced by $18,700,000, or over 17% from last year. This marked the sixth consecutive year of reducing the Company's net debt, with aggregate total reduction of $205,800,000, or approximately 70%. The Company remains focused on executing its strategic business initiatives and continues to evaluate allocation of capital and other uses of free cash to return value to shareholders, while also reducing debt.

On October 22, 2025, Core's Board of Directors ("Board") announced a quarterly cash dividend of $0.01 per share of common stock, which was paid on November 24, 2025, to shareholders of record on November 3, 2025.

On February 4, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on March 9, 2026, to shareholders of record on February 16, 2026.

*<u>Return On Invested Capital</u>*

The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promotes capital efficiency and are designed to produce more predictable and superior long-term ROIC.

The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield services companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg's formula, the Company's ROIC for the fourth quarter of 2025 at 9.7%.

*<u>Industry and Core Lab Outlook and Guidance</u>* 

The IEA, EIA, and OPEC+ forecast global crude oil demand growth of approximately 0.9–1.4 million barrels per day in 2026, a slight increase from their previous forecasts. As discussed in Core Lab's third quarter release, the IEA published a report in September 2025 which noted accelerating natural decline

------

rates in existing producing fields pose a significant long-term supply risk. This analysis underpins the need for sustained investment in oil and gas developments to maintain energy security and market stability. In the U.S., oil production growth is moderating as capital discipline, maturing shale plays, and natural decline rates increasingly offset efficiency gains. As efficiency gains become less impactful, activity levels must increase to maintain or expand U.S. land production. These factors support the ongoing demand for oilfield services, and Core Lab is seeing operators prioritize production sustainment, well optimization, and recovery enhancement. International markets continue to exhibit resilient activity levels indicative of multi-year offshore developments and long-cycle investments across key global basins. Core Lab's Reservoir Description and Production Enhancement technologies are well positioned to support these ongoing investment needs.

In the near term, tariff pressures and OPEC+ production policy decisions continue to contribute to market volatility and softer commodity prices. Despite these headwinds, longer-term crude oil demand fundamentals remain strong. Core Lab maintains a constructive multi-year outlook and continues to see steady activity across committed long-cycle projects, including deepwater developments in the South Atlantic Margin, North and West Africa, Norway, the Middle East, and select Asia-Pacific markets. Revenue realization on these projects remains partially dependent on the geologic success rates achieved by clients. Short-cycle activities, particularly in the U.S. onshore environment, will remain sensitive to changes in commodity prices.

Geopolitical conflicts and associated sanctions, evolving trade and tariff dynamics, and commodity price volatility continue to create uncertainty in demand for Core Lab's products and services. Core also expects seasonal patterns to result in the typical sequential decline in activity during the first quarter of 2026. Severe weather events in North America caused freezing conditions in early 2026 that disrupted both Reservoir Description and Production Enhancement client activities and Core Lab operations. In addition, adverse weather in Europe and the Mediterranean Sea also suspended client crude-assay work and damaged one of the Company's facilities. While client operations have begun to recover, these weather-related disruptions have created additional revenue and margin headwinds for the first quarter.

For the first half of 2026, Core Lab anticipates U.S. land completion activity will be down compared to the first half of 2025; however, the Company projects completion activity to improve from current levels. Growth in demand for Core's diagnostic services and technological innovations in proprietary energetic systems may partially offset softer U.S. onshore activity in 2026.

To date, tariffs have not had a significant impact to Core Lab's Reservoir Description segment. However, for Production Enhancement operations, certain imported raw materials are subject to tariffs. While tariffs are increasing supply costs and affecting margins, the Company continues to take steps to mitigate their impact.

Consequently, Reservoir Description's first quarter 2026 revenue is projected to range from $82,000,000 to $86,000,000,with operating income of $6,800,000 to $8,250,000. Production Enhancement's first quarter revenue is estimated to range from $42,000,000 to $44,000,000, with operating income of $2,800,000 to $3,800,000.

------

Core's first quarter 2026 revenue is projected to range from $124,000,000 to $130,000,000, with operating income of $9,700,000 to $12,200,000, yielding operating margins of approximately 9%. EPS for the first quarter of 2026 is expected to be $0.11 to $0.15.

The Company's first quarter 2026 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. The first quarter guidance also reflects a higher interest rate related to a term loan drawn upon on January 12, 2026, in the amount of $50,000,000. The term loan was used to repay the 2021 Senior Notes Series A in the amount of $45,000,000. This term loan is subject to a variable SOFR-based interest rate in line with our revolving credit facility, which is approximately 200 basis points higher than the fixed rate debt that was retired. First quarter guidance assumes an effective tax rate of 25%.

*<u>Earnings Call Scheduled</u>*

The Company has scheduled a conference call to discuss Core's fourth quarter and full year 2025 earnings announcement. The call will begin at 7:30 a.m. CST / 8:30 a.m. EST on Thursday, February 5, 2026. To log on to the listen-only webcast, visit www.corelab.com/investors 15 minutes before the start of the call. For those not available to listen to the live webcast, a replay and transcript will be available on the Company's website shortly after the call. Analysts may contact investor.relations@corelab.com for conference call dial-in information.

Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements Core Lab makes, includes forward-looking statements regarding the Company's future revenue, profitability, business strategies and developments, demand for the Company's products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the impact of tariffs, trade policies and sanctions, international markets, international political climates, including the Russia-Ukraine and the Middle East geopolitical conflicts, public health crises, and any related actions taken by businesses and governments, and other factors as more fully described in the Company's most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. These important factors could cause the Company's actual results to differ materially from those described in these forward-looking statements. Such statements are based on current expectations of the Company's performance and are subject to a variety of factors, some of which are not under the control of the Company. Because the information herein is based solely on data currently available, and because it is subject to change as a result of changes in conditions over which the Company has no control or influence, such forward-looking statements should not be viewed as assurance regarding the Company's future performance.

The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.

------

Visit the Company's website at www.corelab.com.

For more information, contact:

Gwen Gresham - SVP Corporate Development and Investor Relations

Phone: +1 713 328 6210

E-mail: investor.relations@corelab.com

------

**CORE LABORATORIES INC. & SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(In thousands, except per share data)

(Unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **% Variance** | **% Variance** |
|  | **December 31, 2025** | **September 30, 2025** | **December 31, 2024** | **vs. Q3-2025** | **vs. Q4-2024** |
| REVENUE | $138255 | $134521 | $129237 | 2.8% | 7.0% |
| OPERATING EXPENSES: |  |  |  |  |  |
| &nbsp;&nbsp;Costs of services and product sales | 109516 | 104901 | 106199 | 4.4% | 3.1% |
| &nbsp;&nbsp;General and administrative expense | 10631 | 10688 | 9080 | (0.5)% | 17.1% |
| &nbsp;&nbsp;Depreciation and amortization | 3668 | 3594 | 3664 | 2.1% | 0.1% |
| &nbsp;&nbsp;Other (income) expense, net | (1392) | (5590) | (3880) | NM | NM |
| &nbsp;&nbsp;Total operating expenses | 122423 | 113593 | 115063 | 7.8% | 6.4% |
| OPERATING INCOME | 15832 | 20928 | 14174 | (24.4)% | 11.7% |
| &nbsp;&nbsp;Interest expense | 2609 | 2650 | 2629 | (1.5)% | (0.8)% |
| &nbsp;&nbsp;Income before income taxes | 13223 | 18278 | 11545 | (27.7)% | 14.5% |
| &nbsp;&nbsp;Income tax expense | 5960 | 3754 | 4076 | 58.8% | 46.2% |
| &nbsp;&nbsp;Net income | 7263 | 14524 | 7469 | (50.0)% | (2.8)% |
| &nbsp;&nbsp;Net income attributable to non-<br> controlling interest | 181 | 285 | 66 | NM | NM |
| &nbsp;&nbsp;Net income attributable to Core <br> Laboratories Inc. | $7082 | $14239 | $7403 | (50.3)% | (4.3)% |
| **Diluted earnings per share** | $0.16 | $0.31 | $0.16 | (48.4)% | —% |
| **Diluted earnings per share attributable to Core Laboratories Inc.** | $0.15 | $0.30 | $0.15 | (50.0)% | —% |
| Diluted weighted average common shares outstanding | 46697 | 47078 | 47773 | (0.8)% | (2.3)% |
| Effective tax rate | 45% | 21% | 35% | NM | NM |
| **SEGMENT INFORMATION:** |  |  |  |  |  |
| **Revenue:** |  |  |  |  |  |
| Reservoir Description | $92282 | $88224 | $86793 | 4.6% | 6.3% |
| Production Enhancement | 45973 | 46297 | 42444 | (0.7)% | 8.3% |
| &nbsp;&nbsp;Consolidated | $138255 | $134521 | $129237 | 2.8% | 7.0% |
| **Operating income:** |  |  |  |  |  |
| Reservoir Description | $12823 | $16574 | $16643 | (22.6)% | (23.0)% |
| Production Enhancement | 3025 | 4379 | (2597) | (30.9)% | 216.5% |
| Corporate and Other | (16) | (25) | 128 | NM | NM |
| &nbsp;&nbsp;Consolidated | $15832 | $20928 | $14174 | (24.4)% | 11.7% |
| *"NM" means not meaningful* |  |  |  |  |  |

---

------

**CORE LABORATORIES INC. & SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(In thousands, except per share data)

(Unaudited)

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** | **% Variance** |
|  | **2025** | **2024** |  |
| REVENUE | $526520 | $523848 | 0.5% |
| OPERATING EXPENSES: |  |  |  |
| &nbsp;&nbsp;Costs of services and product sales | 417587 | 420522 | (0.7)% |
| &nbsp;&nbsp;General and administrative expense | 45430 | 39770 | 14.2% |
| &nbsp;&nbsp;Depreciation and amortization | 14649 | 14953 | (2.0)% |
| &nbsp;&nbsp;Other (income) expense, net | (7614) | (9953) | NM |
| &nbsp;&nbsp;Total operating expenses | 470052 | 465292 | 1.0% |
| OPERATING INCOME | 56468 | 58556 | (3.6)% |
| &nbsp;&nbsp;Interest expense | 10572 | 12369 | (14.5)% |
| &nbsp;&nbsp;Income before income taxes | 45896 | 46187 | (0.6)% |
| &nbsp;&nbsp;Income tax expense | 13371 | 14034 | (4.7)% |
| &nbsp;&nbsp;Net income | 32525 | 32153 | 1.2% |
| &nbsp;&nbsp;Net income attributable to non-controlling interest | 722 | 753 | NM |
| &nbsp;&nbsp;Net income attributable to Core Laboratories Inc. | $31803 | $31400 | 1.3% |
| **Diluted earnings per share** | $0.69 | $0.67 | 3.0% |
| **Diluted earnings per share attributable to Core Laboratories Inc.** | $0.68 | $0.66 | 3.0% |
| Diluted weighted average common shares outstanding | 47028 | 47685 | (1.4)% |
| Effective tax rate | 29% | 30% | NM |
| **SEGMENT INFORMATION:** |  |  |  |
| **Revenue:** |  |  |  |
| Reservoir Description | $347683 | $346146 | 0.4% |
| Production Enhancement | 178837 | 177702 | 0.6% |
| &nbsp;&nbsp;Total | $526520 | $523848 | 0.5% |
| **Operating income:** |  |  |  |
| Reservoir Description | $43939 | $51466 | (14.6)% |
| Production Enhancement | 12055 | 6612 | 82.3% |
| Corporate and Other | 474 | 478 | (0.8)% |
| &nbsp;&nbsp;Total | $56468 | $58556 | (3.6)% |
| *"NM" means not meaningful* |  |  |  |

---

------

**CORE LABORATORIES INC. & SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

(In thousands)

(Unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | **% Variance** | **% Variance** |
| **ASSETS:** | **December 31, 2025** | **September 30, 2025** | **December 31, 2024** | **vs. Q3-2024** | **vs. Q4-2024** |
| Cash and cash equivalents | $22847 | $25629 | $19157 | (10.9)% | 19.3% |
| Accounts receivable, net | 113528 | 110258 | 111761 | 3.0% | 1.6% |
| Inventories | 54496 | 58241 | 59402 | (6.4)% | (8.3)% |
| Other current assets | 31495 | 32786 | 36286 | (3.9)% | (13.2)% |
| &nbsp;&nbsp;Total current assets | 222366 | 226914 | 226606 | (2.0)% | (1.9)% |
| Property, plant and equipment, net | 99447 | 98031 | 97063 | 1.4% | 2.5% |
| Right of use assets | 54346 | 53980 | 56488 | 0.7% | (3.8)% |
| Intangibles, goodwill and other long-term assets, net | 220793 | 212435 | 210249 | 3.9% | 5.0% |
| &nbsp;&nbsp;Total assets | $596952 | $591360 | $590406 | 0.9% | 1.1% |
| **LIABILITIES AND EQUITY:** |  |  |  |  |  |
| Accounts payable | $37275 | $36945 | $34549 | 0.9% | 7.9% |
| Short-term operating lease liabilities | 11456 | 11474 | 10690 | (0.2)% | 7.2% |
| Other current liabilities | 58440 | 47324 | 52347 | 23.5% | 11.6% |
| &nbsp;&nbsp;Total current liabilities | 107171 | 95743 | 97586 | 11.9% | 9.8% |
| Long-term debt, net | 110255 | 114103 | 126111 | (3.4)% | (12.6)% |
| Long-term operating lease liabilities | 42309 | 41525 | 43343 | 1.9% | (2.4)% |
| Other long-term liabilities | 57457 | 62601 | 65630 | (8.2)% | (12.5)% |
| Total equity | 279760 | 277388 | 257736 | 0.9% | 8.5% |
| &nbsp;&nbsp;Total liabilities and equity | $596952 | $591360 | $590406 | 0.9% | 1.1% |

---

------

**CORE LABORATORIES INC. & SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(In thousands)

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2025** | **2024** |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Net income | $32525 | $32153 |
| &nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;Stock-based compensation | 7137 | 3755 |
| &nbsp;&nbsp;Depreciation and amortization | 14649 | 14953 |
| &nbsp;&nbsp;Deferred income taxes | (4739) | 674 |
| &nbsp;&nbsp;Insurance recovery on property, plant and equipment | (6830) | (4398) |
| &nbsp;&nbsp;Accounts receivable | (4953) | (3612) |
| &nbsp;&nbsp;Inventories | 2644 | 9367 |
| &nbsp;&nbsp;Accounts payable | 477 | 519 |
| &nbsp;&nbsp;Other adjustments to net income | (3734) | 2977 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | 37176 | 56388 |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Capital expenditures - operations | (11209) | (11888) |
| &nbsp;&nbsp;Capital expenditures - rebuilding of Aberdeen facility | (3380) | (1140) |
| &nbsp;&nbsp;Net proceeds from insurance recovery - Aberdeen facility | 9951 | 2102 |
| &nbsp;&nbsp;Acquisitions, net of cash acquired | (1237) |  |
| &nbsp;&nbsp;Net proceeds from life insurance policies | 778 | 2776 |
| &nbsp;&nbsp;Other investing activities | 2866 | 1756 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in investing activities** | (2231) | (6394) |
| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
| Repayment of long-term debt | (63000) | (82000) |
| &nbsp;&nbsp;Proceeds from long-term debt | 48000 | 44000 |
| &nbsp;&nbsp;Equity related transaction costs |  | (756) |
| &nbsp;&nbsp;Debt issuance costs | (1706) | (19) |
| &nbsp;&nbsp;Dividends paid | (1869) | (1876) |
| &nbsp;&nbsp;Repurchase of common stock | (12426) | (5306) |
| &nbsp;&nbsp;Other financing activities | (254) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in financing activities** | (31255) | (45957) |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 3690 | 4037 |
| CASH AND CASH EQUIVALENTS, beginning of year | 19157 | 15120 |
| CASH AND CASH EQUIVALENTS, end of year | $22847 | $19157 |

---

------

**<u>Non-GAAP Information</u>**

Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.

**Reconciliation of Operating Income, Net Income and Diluted Earnings Per Share Attributable to Core Laboratories Inc.**

(In thousands, except per share data)

(Unaudited)

---

| | | | |
|:---|:---|:---|:---|
|  | **Operating Income** | **Operating Income** | **Operating Income** |
|  | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** |
|  | **December 31, 2025** | **September 30, 2025** | **December 31, 2024** |
| GAAP reported | $15832 | $20928 | $14174 |
| Stock compensation <sup>(1)</sup> |  |  | (771) |
| Inventory and asset write-downs and severance <sup>(2)</sup> |  | 601 | 4115 |
| Insurance recovery on property, plant and equipment <sup>(3)</sup> |  | (5252) | (2572) |
| Foreign exchange losses (gains) | (95) | 354 | 761 |
| Excluding specific items | $15737 | $16631 | $15707 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Net Income Attributable to Core Laboratories Inc.** | **Net Income Attributable to Core Laboratories Inc.** | **Net Income Attributable to Core Laboratories Inc.** |
|  | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** |
|  | **December 31, 2025** | **September 30, 2025** | **December 31, 2024** |
| GAAP reported | $7082 | $14239 | $7403 |
| Stock compensation <sup>(1)</sup> |  |  | (617) |
| Inventory and asset write-downs and severance <sup>(2)</sup> |  | 451 | 3292 |
| Insurance recovery on property, plant and equipment <sup>(3)</sup> |  | (3939) | (2058) |
| Foreign exchange losses (gains) | (72) | 265 | 610 |
| Effect of higher (lower) tax rate <sup>(4</sup><sup>)</sup> | 2654 | (815) | 1766 |
| Excluding specific items | $9664 | $10201 | $10396 |

---

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Diluted Earnings Per Share Attributable to Core Laboratories Inc.** | **Diluted Earnings Per Share Attributable to Core Laboratories Inc.** | **Diluted Earnings Per Share Attributable to Core Laboratories Inc.** | **Diluted Earnings Per Share Attributable to Core Laboratories Inc.** | **Diluted Earnings Per Share Attributable to Core Laboratories Inc.** | **Diluted Earnings Per Share Attributable to Core Laboratories Inc.** | **Diluted Earnings Per Share Attributable to Core Laboratories Inc.** | **Diluted Earnings Per Share Attributable to Core Laboratories Inc.** |
|  | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Year ended** | **Year ended** |
|  | **December 31, 2025** | **December 31, 2025** | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2025** | **December 31, 2025** |
| GAAP reported | $| 0.15 | $| 0.30 | $| 0.15 | $| 0.68 |
| Stock compensation <sup>(1)</sup> |  |  |  |  |  | (0.01) |  | 0.05 |
| Inventory and asset write-downs, lease abandonment and severance <sup>(2)</sup> |  |  |  | 0.01 |  | 0.07 |  | 0.08 |
| Insurance recovery on property, plant and equipment <sup>(3)</sup> |  |  |  | (0.08) |  | (0.04) |  | (0.11) |
| Foreign exchange losses (gains) |  |  |  | 0.01 |  | 0.01 |  | 0.01 |
| Effect of higher (lower) tax rate <sup>(4</sup><sup>)</sup> |  | 0.06 |  | (0.02) |  | 0.04 |  | 0.04 |
| Excluding specific items | $ | 0.21 | $ | 0.22 | $ | 0.22 | $ | 0.75 |
| *(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age.* | *(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age.* | *(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age.* | *(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age.* | *(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age.* | *(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age.* | *(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age.* | *(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age.* | *(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age.* |
| *(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities.* | *(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities.* | *(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities.* | *(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities.* | *(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities.* | *(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities.* | *(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities.* | *(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities.* | *(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities.* |
| *(3) Includes recovery of insurance proceeds associated with the fire at the Aberdeen, U.K. facility.* | *(3) Includes recovery of insurance proceeds associated with the fire at the Aberdeen, U.K. facility.* | *(3) Includes recovery of insurance proceeds associated with the fire at the Aberdeen, U.K. facility.* | *(3) Includes recovery of insurance proceeds associated with the fire at the Aberdeen, U.K. facility.* | *(3) Includes recovery of insurance proceeds associated with the fire at the Aberdeen, U.K. facility.* | *(3) Includes recovery of insurance proceeds associated with the fire at the Aberdeen, U.K. facility.* | *(3) Includes recovery of insurance proceeds associated with the fire at the Aberdeen, U.K. facility.* | *(3) Includes recovery of insurance proceeds associated with the fire at the Aberdeen, U.K. facility.* | *(3) Includes recovery of insurance proceeds associated with the fire at the Aberdeen, U.K. facility.* |
| *(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of 20%. The three months ended September 30, 2025 and December 31, 2025, and the year ended December 31, 2025 include the effect to reflect tax expense at a normalized rate of 25%.* | *(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of 20%. The three months ended September 30, 2025 and December 31, 2025, and the year ended December 31, 2025 include the effect to reflect tax expense at a normalized rate of 25%.* | *(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of 20%. The three months ended September 30, 2025 and December 31, 2025, and the year ended December 31, 2025 include the effect to reflect tax expense at a normalized rate of 25%.* | *(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of 20%. The three months ended September 30, 2025 and December 31, 2025, and the year ended December 31, 2025 include the effect to reflect tax expense at a normalized rate of 25%.* | *(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of 20%. The three months ended September 30, 2025 and December 31, 2025, and the year ended December 31, 2025 include the effect to reflect tax expense at a normalized rate of 25%.* | *(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of 20%. The three months ended September 30, 2025 and December 31, 2025, and the year ended December 31, 2025 include the effect to reflect tax expense at a normalized rate of 25%.* | *(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of 20%. The three months ended September 30, 2025 and December 31, 2025, and the year ended December 31, 2025 include the effect to reflect tax expense at a normalized rate of 25%.* | *(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of 20%. The three months ended September 30, 2025 and December 31, 2025, and the year ended December 31, 2025 include the effect to reflect tax expense at a normalized rate of 25%.* | *(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of 20%. The three months ended September 30, 2025 and December 31, 2025, and the year ended December 31, 2025 include the effect to reflect tax expense at a normalized rate of 25%.* |

---

**Segment Information**

(In thousands)

(Unaudited)

---

| | | | |
|:---|:---|:---|:---|
|  | **Operating Income** | **Operating Income** | **Operating Income** |
|  | **Quarter Ended December 31, 2025** | **Quarter Ended December 31, 2025** | **Quarter Ended December 31, 2025** |
|  | **Reservoir Description** | **Production Enhancement** | **Corporate and Other** |
| GAAP reported | $12823 | $3025 | $(16) |
| Foreign exchange losses (gains) | (111) | 3 | 13 |
| Excluding specific items | $12712 | $3028 | $(3) |

---

*<u>Return on Invested Capital</u>*

Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful information to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.

ROIC of 9.7% is defined by Bloomberg as Net Operating Profit After Tax ("NOPAT") of $38.8 million divided by Average Total Invested Capital ("Average TIC") of $398.5 million, where NOPAT is defined as GAAP net income before non-controlling interest *plus* the sum of income tax expense, interest expense, and pension expense, *less* pension service cost and tax effect on income before interest and tax expense for the last four quarters. Average TIC is defined as the average of beginning and ending periods' GAAP stockholders' equity, *plus* the sum of net long-term debt, lease liabilities, allowance for credit losses, net of deferred taxes and income taxes payable.

------

*<u>Free Cash Flow</u>*

Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) *less* cash paid for capital expenditures - operations. Management believes that free cash flow provides useful information to investors regarding the cash available in the period in excess of Core's needs to fund its capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash does not represent residual cash available for distribution because Core may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.

**Computation of Free Cash Flow**

(In thousands)

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Quarter Ended** | **Year Ended** |
|  | **December 31, 2025** | **December 31, 2025** |
| Net cash provided by operating activities | $8091 | $37176 |
| Capital expenditures - operations | (2944) | (11209) |
| Free cash flow | $5147 | $25967 |

---

###

------